🧬 Longevity Peptides

A synthetic tetrapeptide that reportedly upregulates telomerase activity. Russian longevity studies suggest mortality reductions but Western RCTs are absent.

Dose: 5–10 mg daily for 10–20 days, cycled (subcutaneous)

A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.

Dose: 5–10 mg, 2–3 times weekly (subcutaneous)

A cell-permeable tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Investigated for primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.

Dose: Trial range: 40 mg subcutaneous daily

A small-molecule NNMT inhibitor that has produced fat loss and improved muscle stem-cell function in obese rodents. No human RCTs yet.

Dose: 50–150 mg orally daily (research-only)

A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.

Dose: 5–10 mg daily for 10–20 days (subcutaneous, cycled)

A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.

Dose: Research range: 0.5–1 mg subcutaneous (rare clinical use)

Technically a tripeptide (γ-glutamyl-cysteinyl-glycine) and the body's primary antioxidant. Often grouped with peptide therapy in IV/compounded form for liver support and oxidative stress.

Dose: 200–600 mg sublingual / 600–2400 mg IV (compounded)